Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.

Yabao Pharmaceutical Group Co., Ltd (SHSE:600351) commences share repurchases on May 8, 2023, under the program mandated by the shareholders in the extraordinary general meeting held on April 24, 2023. As per the mandate, the company is authorized to repurchase up to CNY 300 million worth of its shares. The shares will be repurchased at a price not more than CNY 7.20 per share.

Repurchases will be funded using the company's own funds. The repurchased shares will be used to cancel and reduce registered capital. The program will be valid for 12 months.